Linear IgA bullous dermatosis in a latin adolescent treated with cyclosporine and prednisone.

Andrea Ríos-Sánchez, Juan A Godínez-Chaparro, Marissa de J Quintal-Ramírez, Ixchel R Ramírez-Ricarte
{"title":"Linear IgA bullous dermatosis in a latin adolescent treated with cyclosporine and prednisone.","authors":"Andrea Ríos-Sánchez, Juan A Godínez-Chaparro, Marissa de J Quintal-Ramírez, Ixchel R Ramírez-Ricarte","doi":"10.24875/BMHIM.24000043","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Linear IgA bullous dermatosis (LABD) is a rare autoimmune disease. Although dapsone is the initial treatment, other immunomodulators are used in resistant cases or when dapsone is unavailable.</p><p><strong>Case report: </strong>A 12-year-old Mexican child, with no relevant medical history, developed in May 2023 a disseminated dermatosis affecting all body segments, including mucous membranes, characterized by erythematous patches and plaques evolving into the formation of serous and serosanguinous blisters and vesicles, distributed in a \"string of pearls\" pattern. LABD was suspected and confirmed by skin biopsy, which showed a subepidermal blister with neutrophilic infiltration and linear Immunoglobulin A deposits at the dermo-epidermal junction by direct immunofluorescence. Treatment with prednisone (2 mg/kg/day) and cyclosporine (5 mg/kg/day) resulted in improvement and lesion remission within 2 weeks. Both drugs needed to be discontinued for 3 months due to intermittent blistering. Cyclosporine was continued as maintenance therapy at a dose of 4 mg/kg/day for 8 months.</p><p><strong>Conclusions: </strong>The report highlights the use of cyclosporine as an alternative immunomodulator for DAAL, an immunosuppressive agent used in autoimmune disorders. Few cases, including this one, have described complete remission and control of the dermatosis with cyclosporine, accompanied by prednisone at the start of treatment.</p>","PeriodicalId":9103,"journal":{"name":"Boletín médico del Hospital Infantil de México","volume":"81 5","pages":"305-310"},"PeriodicalIF":0.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Boletín médico del Hospital Infantil de México","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/BMHIM.24000043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Linear IgA bullous dermatosis (LABD) is a rare autoimmune disease. Although dapsone is the initial treatment, other immunomodulators are used in resistant cases or when dapsone is unavailable.

Case report: A 12-year-old Mexican child, with no relevant medical history, developed in May 2023 a disseminated dermatosis affecting all body segments, including mucous membranes, characterized by erythematous patches and plaques evolving into the formation of serous and serosanguinous blisters and vesicles, distributed in a "string of pearls" pattern. LABD was suspected and confirmed by skin biopsy, which showed a subepidermal blister with neutrophilic infiltration and linear Immunoglobulin A deposits at the dermo-epidermal junction by direct immunofluorescence. Treatment with prednisone (2 mg/kg/day) and cyclosporine (5 mg/kg/day) resulted in improvement and lesion remission within 2 weeks. Both drugs needed to be discontinued for 3 months due to intermittent blistering. Cyclosporine was continued as maintenance therapy at a dose of 4 mg/kg/day for 8 months.

Conclusions: The report highlights the use of cyclosporine as an alternative immunomodulator for DAAL, an immunosuppressive agent used in autoimmune disorders. Few cases, including this one, have described complete remission and control of the dermatosis with cyclosporine, accompanied by prednisone at the start of treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用环孢素和泼尼松治疗一名拉丁裔青少年的线性 IgA 大疱性皮肤病。
简介线性 IgA 大疱性皮肤病(LABD)是一种罕见的自身免疫性疾病。虽然多泼松是最初的治疗方法,但在耐药病例或无法使用多泼松时,也会使用其他免疫调节剂:病例报告:一名 12 岁的墨西哥儿童,无相关病史,于 2023 年 5 月患上播散性皮炎,累及全身各处,包括粘膜,以红斑和斑块演变为浆液性和浆液性水疱和囊泡为特征,呈 "珍珠串 "状分布。直接免疫荧光显示表皮下水疱有中性粒细胞浸润,真皮表皮交界处有线状免疫球蛋白 A 沉积。使用泼尼松(2 毫克/千克/天)和环孢素(5 毫克/千克/天)治疗后,病情得到改善,皮损在两周内缓解。由于出现间歇性水疱,两种药物均需停用 3 个月。环孢素的维持治疗剂量为4毫克/千克/天,持续了8个月:本报告强调了环孢素作为 DAAL 的替代免疫调节剂的用途,DAAL 是一种用于自身免疫性疾病的免疫抑制剂。包括本病例在内,很少有病例描述使用环孢素后皮肤病得到完全缓解和控制,治疗开始时还伴有泼尼松。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
73
审稿时长
20 weeks
期刊介绍: The Boletín Médico del Hospital Infantil de México is a bimonthly publication edited by the Hospital Infantil de México Federico Gómez. It receives unpublished manuscripts, in English or Spanish, relating to paediatrics in the following areas: biomedicine, clinical, public health, clinical epidemology, health education and clinical ethics. Articles can be original research articles, in-depth or systematic reviews, clinical cases, clinical-pathological cases, articles about public health, letters to the editor or editorials (by invitation).
期刊最新文献
Acknowledgments to reviewers 2023. Analysis of the changes in the management of preterm newborns born in a Spanish third-level hospital in the past 10 years. Changes in Neonatal Intensive Care Unit statistics during the COVID-19 pandemic. Comparison between the KARVI scale and the Child Development Evaluation test (EDI) as a screening tool for suspected neurodevelopmental delay. Dietary patterns of Sonoran breastfeeding women are associated to exclusive or partial breastfeeding regimes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1